Liu W, Lang M, Youdim MB, Amit T, Sun Y, Zhang Z, Wang Y, Weinreb O (2016)
Design, synthesis and evaluation of novel dual monoamine-cholinesterase inhibitors as potential treatment for Alzheimer's disease
Neuropharmacology 109: 376

Weinreb O, Amit T, Bar-Am O, Youdim MB (2016)
Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and beta-amyloid in ageing and Alzheimer's disease
British Journal of Pharmacology 173: 2080

Weinreb O, Amit T, Bar-Am O, Youdim MB (2012)
Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment
Curr Drug Targets 13: 483

Zheng H, Amit T, Bar-Am O, Fridkin M, Youdim MB, Mandel SA (2012)
From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease
J Alzheimers Dis 30: 1

Weinreb O, Amit T, Bar-Am O, Youdim MB (2011)
A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor
International Review of Neurobiology 100: 191

Bar-Am O, Amit T, Weinreb O, Youdim MB, Mandel S (2010)
Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation
J Alzheimers Dis 21: 361

Bar-Am O, Weinreb O, Amit T, Youdim MB (2009)
The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats
Journal of Molecular Neuroscience 37: 135

Weinreb O, Mandel S, Bar-Am O, Yogev-Falach M, Avramovich-Tirosh Y, Amit T, Youdim MB (2009)
Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs
Neurotherapeutics 6: 163

Weinreb O, Amit T, Bar-Am O, Yogev-Falach M, Youdim MB (2008)
The neuroprotective mechanism of action of the multimodal drug ladostigil
Front Biosci 13: 5131

Weinreb O, Bar-Am O, Amit T, Drigues N, Sagi Y, Youdim MB (2008)
The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity
Chemico-Biological Interactions 175: 318

Bar-Am O, Amit T, Youdim MB (2007)
Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro
Journal of Neurochemistry 103: 500

Yogev-Falach M, Bar-Am O, Amit T, Weinreb O, Youdim MB (2006)
A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing
FASEB Journal 20: 2177

Youdim MB, Amit T, Bar-Am O, Weinreb O, Yogev-Falach M (2006)
Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil
Neurotox Res 10: 181

Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T (2005)
Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition
Journal of Neuroscience Research 79: 172

Bar-Am O, Yogev-Falach M, Amit T, Sagi Y, Youdim MB (2004)
Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo
Journal of Neurochemistry 89: 1119

Youdim MB, Amit T, Avramovich Y, Bar-Am O, Weinstock M, Yogev-Falach M (2004)
PKC and MAP kinase-dependent processing of amyloid precursor protein (APP) by neuroprotective propargylamine cholinesterase inhibitors derived from rasagiline and nonsteroidal anti-inflammatory drugs.
Cholinergic Mechanisms, CRC Press

Youdim MB, Sagi Y, Derigus N, Naoi M, Maruyama W, Amit T, Falash-Yogev M, Weinstock M (2004)
Poster (57) A novel neuroprotective trifunctional cholinesterase inhibitor derivative of the antiparkinson drug, rasagiline, for treatment of dementia and lewy body disease co-morbid with depression
In: Cholinesterases in the Second Millennium: Biomolecular and Pathological Aspects (Inestrosa NC, Campos EO) P. Universidad Catolica de Chile-FONDAP Biomedicina: 351

Youdim MB, Amit T, Bar-Am O, Weinstock M, Yogev-Falach M (2003)
Amyloid Processing and Signal Transduction Properties of Antiparkinson-Antialzheimer Neuroprotective Drugs Rasagiline and TV3326
Annals of the New York Academy of Sciences 993: 378

Yogev-Falach M, Amit T, Bar-Am O, Weinstock M, Youdim MB (2002)
The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline
FASEB Journal 16: 1674